Methods for treating liver tissue

Abstract

Methods and kits are provided for administering a hypoxia-activated bioreductive agent by applying the agent locally to liver tissue when hepatic arterial pressure is reduced. Local arterial application when pressure is reduced tissue prolongs the duration of tissue exposure to the hypoxia-activated bioreductive agent. Hepatic pressure may be reduced proximal to the liver tissue. In some embodiments, local application may be followed by embolization when arterial pressure is reduced. Embolization under reduced pressure may decrease complications associated with backflow and increase the efficacy of the hypoxia-activated agent.

Description

[0001] cross reference [0002] This PCT application claims priority to U.S. Provisional Patent Application No. 62 / 336,498 filed May 13, 2016, which is hereby incorporated by reference in its entirety for all purposes. Background technique [0003] Liver cancer can originate in the liver or derive from metastatic cancer in other organs, such as from colorectal, breast, or lung cancers. The most common type of liver cancer is hepatocellular carcinoma [0004] (HCC), accounting for approximately 75% of all liver cancers. Other types of liver cancer include fibrolamellar hepatocellular carcinoma, cholangiocarcinoma, and angiosarcoma. [0005] Liver cancer is the fifth leading cause of cancer-related death in the world. The highest incidence in the world is in Asia, which accounts for the majority of all known liver cancer incidence worldwide. In Asia, very high incidence rates can be seen in China, Korea, and Japan, with some registries showing rates higher than 20 / 100,000 i...

AI Technical Summary

Problems solved by technology

Non-targeted therapies for liver treatment, such as conventional chemotherapy and radiation therapy, are not particularly effective and carry risks including systemic exposure to chemotherapeutic agents and ionizing radiation

Images